Smartcells, Inc.

Beverly, MA 01951

SBIR Award Summary

Total Number of Awards 12
Total Value of Awards $8.31MM
First Award Date 09/30/04
Most Recent Award Date 09/01/10

Key Personnel

Last Name Name Awards Contact
Zion Todd C Zion 12

12 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 09/01/10 - 08/31/11

DESCRIPTION (provided by applicant): SmartCells is developing SmartInsulin?,which is intended to be a once-a-day, self- regulating insulin injection for the treatment of Type I diabetes. It is designed as a "drop- in" replacement product for the 4 million insulin-using diabetics in the United States. SmartInsulin is designed to provide significa...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 09/25/09 - 08/31/10

DESCRIPTION (provided by applicant): SmartCells is developing SmartInsulin?,which is intended to be a once-a-day, self- regulating insulin injection for the treatment of Type I diabetes. It is designed as a "drop- in" replacement product for the 4 million insulin-using diabetics in the United States. SmartInsulin is designed to provide significa...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-013
Budget: 08/01/09 - 07/31/10

DESCRIPTION (provided by applicant): The Company is developing SmartInsulin(tm), which is intended to be a once-a-day, self- regulating insulin injection for the treatment of Type I diabetes. It is designed as a "drop- in" replacement product for the 4 million insulin-using diabetics in the United States. SmartInsulin is designed to provide sign...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-13
Budget: 08/01/08 - 07/31/09

DESCRIPTION (provided by applicant): The Company is developing SmartInsulin(tm), which is intended to be a once-a-day, self- regulating insulin injection for the treatment of Type I diabetes. It is designed as a "drop- in" replacement product for the 4 million insulin-using diabetics in the United States. SmartInsulin is designed to provide sign...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-DK-05-16
Budget: 04/01/08 - 03/31/09

DESCRIPTION (provided by applicant): The landmark Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS), have clinically proven that tighter glycemic control, as measured by lower glycosylated hemoglobin A1c (HbA1c) levels, significantly reduces the incidence of diabetic complications. True glycemic cont...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 03/17/08 - 02/28/09

DESCRIPTION (provided by applicant): SmartCells is developing SmartInsulin", which is intended to be a once-a-day, self- regulating insulin injection for the treatment of Type I diabetes. It is designed as a "drop- in" replacement product for the 4 million insulin-using diabetics in the United States. SmartInsulin is designed to provide signific...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-13
Budget: 08/01/07 - 07/31/08

DESCRIPTION (provided by applicant): The Company is developing SmartInsulin(tm), which is intended to be a once-a-day, self- regulating insulin injection for the treatment of Type I diabetes. It is designed as a "drop- in" replacement product for the 4 million insulin-using diabetics in the United States. SmartInsulin is designed to provide sign...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-DK-05-16
Budget: 04/01/07 - 03/31/08

DESCRIPTION (provided by applicant): The landmark Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS), have clinically proven that tighter glycemic control, as measured by lower glycosylated hemoglobin A1c (HbA1c) levels, significantly reduces the incidence of diabetic complications. True glycemic cont...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/06 - 06/30/07

DESCRIPTION (provided by applicant): SmartCells has developed Smartlnsulin, a once-a-day, injectable formulation of insulin for the treatment of diabetes. Unlike pump- and cell-based systems, Smartlnsulin is a "smart" hydrogel that self-assembles from two biomolecular building blocks: a glycosylated insulin-polymer conjugate (IPC) and a multimer...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-25
Budget: 09/01/05 - 08/31/06

DESCRIPTION (provided by applicant): SmartCells has developed Smartlnsulin, a once-a-day, injectable formulation of insulin for the treatment of diabetes. True glycemic control requires treatments that provide plasma glucose-regulated insulin replacement. Smartlnsulin, which senses and responds to altered serum glucose levels in a clinically re...

Load More